{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-24-000030","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.195539+00:00","generated_at":"2026-05-30T08:45:33.302441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60","bullets":["Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.","Non-GAAP diluted EPS $4.08 (-6% YoY); FY2024 Non-GAAP EPS guidance raised to $16.10-$16.60 (~11% growth at midpoint).","LEQEMBI global in-market sales ~$67M (US $39M); other launches delivered sequential revenue growth.","Dapirolizumab pegol Phase 3 met primary endpoint in SLE; second Phase 3 study to initiate in 2024.","Nusinersen higher dose showed statistically significant improvement; global regulatory submissions planned."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-24-000030","json":"https://secwatch.observer/filing/0000875045-24-000030.json","markdown":"https://secwatch.observer/filing/0000875045-24-000030.md","text":"https://secwatch.observer/filing/0000875045-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/0000875045-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/biib-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:45:33.302441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}